Johnson & Johnson Tops Q1 Estimates, Lifts Full-Year Sales Outlook

Johnson & Johnson (JNJ) on Tuesday expected a better quarter results and removed its sales forecast for the whole year.

The Pharmaceutical and Medical Technology firm posted an adjusted income of $ 2.77 per share (EPS) on revenue of $ 21.89 billion. Analysts expected $ 2.56 and $ 21.56 billion respectively, according to estimates compiled by visible alpha.

Soon after the report, Johnson & Johnson shares were up to about 1%. He entered about 7% day since the beginning of the year.

The company raised its estimated sales range to $ $ 91.0 billion to $ 91.8 billion, which increased from $ 89.2 billion to $ $ 90.0 billion to $ 90.0 billion. It kept its adjusted EPS forecasts stable at $ 10.50 to $ 10.70, including the tariff cost, weakened from the acquisition of intra-cellular therapy, and updated foreign currency. ”

Since reporting a disappointing 2025 sales approach in January, the company discontinued its approximately $ 15 billion acquisition of intra-cellular therapy and announced a plan to increase its US investment by more than $ 55 billion over the next four years.

Johnson & Johnson Stock slipped earlier this month, when a judge dismissed his proposed “prepacked bankruptcy scheme” for an assistant, which would accuse thousands of claims of disposing of his Talk products due to cancer.